- Home
- NBXG vs IMCR Comparison
NBXG vs IMCR Comparison
Compare NBXG & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBXG | IMCR |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | NBXG | IMCR |
|---|---|---|
| Price | $16.12 | $32.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $66.33 |
| AVG Volume (30 Days) | 243.2K | ★ 648.0K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | N/A | $14.57 |
| Revenue Next Year | N/A | $8.21 |
| P/E Ratio | ★ N/A | $132.32 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $12.32 | $27.56 |
| 52 Week High | $17.43 | $40.71 |
Technical Indicators
Market Signals| Indicator | NBXG | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 57.21 |
| Support Level | $15.45 | $31.02 |
| Resistance Level | $17.19 | $33.32 |
| Average True Range (ATR) | 0.50 | 1.34 |
| MACD | -0.07 | 0.25 |
| Stochastic Oscillator | 32.75 | 64.12 |
Price Performance
Historical ComparisonAbout NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.